Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma

References

• AsamuraHGoyaTKoshiishiYA Japanese Lung Cancer Registry Study: prognosis of 13,010 resected lung cancersJ Thorac Oncol20083465218166840
   PubMed Web of Science ®Google Scholar
• SawabataNMiyaokaEAsamuraHJapanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decadeJ Thorac Oncol201161229123521610521
   PubMed Web of Science ®Google Scholar
• ShimizuKOkitaRNakataMClinical significance of the tumor microenvironment in non-small cell lung cancerAnn Transl Med201312025332964
   PubMedGoogle Scholar
• FreemanGJLongAJIwaiYEngagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activationJ Exp Med20001921027103411015443
   PubMed Web of Science ®Google Scholar
• BlankCGajewskiTFMackensenAInteraction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapyCancer Immunol Immunother20055430731415599732
   PubMed Web of Science ®Google Scholar
• WeberJSD’AngeloSPMinorDNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialLancet Oncol20151637538425795410
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med201537312313526028407
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med20153731627163926412456
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet20163871540155026712084
   PubMed Web of Science ®Google Scholar
• ReckMRodríguez-AbreuDRobinsonAGPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med20163751823183327718847
   PubMed Web of Science ®Google Scholar
• VelchetiVSchalperKACarvajalDEProgrammed death ligand-1 expression in non-small cell lung cancerLab Invest20149410711624217091
   PubMed Web of Science ®Google Scholar
• ShimojiMShimizuSSatoKClinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)Lung Cancer201698697527393509
   PubMed Web of Science ®Google Scholar
• SunJMZhouWChoiYLPrognostic significance of PD-L1 in patients with non-small cell lung cancer: a large cohort study of surgically resected casesJ Thorac Oncol2016111003101127103510
   PubMed Web of Science ®Google Scholar
• YangCYLinMWChangYLWuCTYangPCProgrammed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomesEur J Cancer2014501361136924548766
   PubMed Web of Science ®Google Scholar
• GalonJCostesASanchez-CaboFType, density, and location of immune cells within human colorectal tumors predict clinical outcomeScience20063131960196417008531
   PubMed Web of Science ®Google Scholar
• ZhangLConejo-GarciaJRKatsarosDIntratumoral T cells, recurrence, and survival in epithelial ovarian cancerN Engl J Med200334820321312529460
   PubMed Web of Science ®Google Scholar
• AliHRProvenzanoEDawsonSJAssociation between CD8+ T-cell infiltration and breast cancer survival in 12,439 patientsAnn Oncol2014251536154324915873
   PubMed Web of Science ®Google Scholar
• KinoshitaTMuramatsuRFujitaTPrognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancerAnn Oncol2016272117212327502728
   PubMed Web of Science ®Google Scholar
• TengFMengXWangXExpressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisionsOncotarget20167643186432927602763
   PubMedGoogle Scholar
• DonnemTHaldSMPaulsenEEStromal CD8+ T-cell density—a promising supplement to TNM staging in non-small cell lung cancerClin Cancer Res2015212635264325680376
   PubMed Web of Science ®Google Scholar
• DuboisRNAbramsonSBCroffordLCyclooxygenase in biology and diseaseFASEB J199812106310739737710
   PubMed Web of Science ®Google Scholar
• HidaTYatabeYAchiwaHIncreased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomasCancer Res199858376137649731479
   PubMed Web of Science ®Google Scholar
• HwangDScollardDByrneJLevineEExpression cyclooxygenase-1 and cyclooxygenase-2 in human breast cancerJ Natl Cancer Inst1998904554609521170
   PubMed Web of Science ®Google Scholar
• OginoSKirknerGJNoshoKCyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancerClin Cancer Res2008148221822719088039
   PubMed Web of Science ®Google Scholar
• GoldstrawPCrowleyJChanskyKThe IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumoursJ Thorac Oncol2007270671417762336
   PubMed Web of Science ®Google Scholar
• TravisWDBrambillaENoguchiMInternational Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinomaJ Thorac Oncol2011624428521252716
   PubMed Web of Science ®Google Scholar
• EdelmanMJWatsonDWangXEicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy – Cancer and Leukemia Group B Trial 30203J Clin Oncol20082684885518281656
   PubMed Web of Science ®Google Scholar
• TengMWNgiowSFRibasASmythMJClassifying cancers based on T cell infiltration and PD-L1Cancer Res2015752139214525977340
   PubMed Web of Science ®Google Scholar
• NagaiYMiyazawaHHuqunGenetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clampCancer Res2005657276728216105816
   PubMed Web of Science ®Google Scholar
• D’InceccoAAndreozziMLudoviniVPD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patientsBr J Cancer20151129510225349974
   PubMed Web of Science ®Google Scholar
• SchalperKABrownJCarvajal-HausdorfDObjective measurement and clinical significance of TILs in non-small cell lung cancerJ Natl Cancer Inst2015107 pii: dju435
   Google Scholar
• KondratievSSaboEYakievichELavieOResnickMBIntratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinomaClin Cancer Res2004104450445615240536
   PubMed Web of Science ®Google Scholar
• ShimizuKNakataMHiramiYYukawaKMaedaATanemotoKTumor-infiltrating Foxp3+ regulatory t cells are correlated with cyclooxygenese-2 expression and are associated with recurrence in resected non-small cell lung cancerJ Thorac Oncol2010558559020234320
   PubMed Web of Science ®Google Scholar
• OhnoYOhnoSSuzukiNRole of cyclooxygenase-2 in immunomodulation and prognosis of endometrial carcinomaInt J Cancer200511469670115609300
   PubMed Web of Science ®Google Scholar
• BottiGFratangeloFCerroneMCOX-2 expression positively correlates with PD-L1 expression in human melanoma cellsJ Transl Med2017154628231855
   PubMed Web of Science ®Google Scholar
• HirschFRMcElhinnyAStanforthDPD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the BLUEPRINT PD-L1 IHC Assay Comparison ProjectJ Thorac Oncol20171220822227913228
   PubMed Web of Science ®Google Scholar